Guobang Pharma Ltd (605507.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100004NS2

Price
14.59 CNY
Market cap
11.41 bn CNY
P/E (2025)
13.91
P/S (2025)
1.90
Dividend yield
2.94 %
Net margin
13.65 %
Return on equity (ROE)
9.60 %
Return on assets (ROA)
7.47 %

Guobang Pharma Ltd financials

Fiscal year20242025
Revenue5.89 bn CNY6.01 bn CNY
Gross profit1.44 bn CNY1.56 bn CNY
Operating income895.07 m CNY961.88 m CNY
EBIT836.84 m CNY975.18 m CNY
Net income781.60 m CNY820.82 m CNY
Diluted EPS – continuing operations1.40 CNY1.05 CNY

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Guobang Pharma Ltd

Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives. It sells its products approximately in 117 countries and regions worldwide. The company was founded in 1996 and is based in Xinchang, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.